Replies to post #203516 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

Still a long way from Nasdaq requirements. Next 6-12 months will be exciting with other near-term submissions.

It does seem this way doesn't it. Well, what does this tell you?

Elite Pharmaceuticals Announces Changes To Their Board Of Directors
Gene Pfeifer Joins Elite's Board

NORTHVALE, N.J., April 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that its Board of Directors has appointed Eugene Pfeifer to its board effective April 7, 2016. At the same meeting, the Board accepted the resignation of Jeenarine Narine.

Mr. Pfeifer brings with him more than 45 years of regulatory and trade experience, most recently having served as a law partner at King & Spalding in Washington DC and prior to that as a law partner at the Burditt, Bowles & Radzius. Among his many accomplishments, he was a major participant in the development of the Drug Price Competition and Patent Term Restoration Act of 1984, and provided strategic counseling to companies affected by that statue. In addition, he has provided regulatory advice and representation on a wide variety of FDA, FTC, and DEA regulated activities, including product approval, advertising, promotion, and compliance issues.

Prior to working at Burditt, Bowles and Radzius, Mr. Pfeifer served for a year in the General Counsel's office of the Federal Trade Commission, where he represented the FTC in Federal Court to enjoin violations of the Federal Trade Commission Act, and served ten years in the Chief Counsel's Office at the FDA as Associated Chief Counsel for Enforcement, Associate Chief Counsel for Drugs and Deputy Chief Counsel for Regulations and Hearings. During his tenure at the FDA, he was the FDA's lead litigator and Appellate Court advocate, and he briefed the FDA's cases before the Supreme Court.